2023 Best Workplaces™ award deadlines are closing soon. Start your application today!

Alnylam Pharmaceuticals

Updated August 2022.

94%

Employees say this is a great place to work

Company Overview

About The Company

Alnylam has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA™ (vutrisiran) and Leqvio® (inclisiran) being developed and commercialized by Novartis.

COMPANY SIZE

1,506 U.S.-based Employees
(Large)

INDUSTRY

Biotechnology & Pharmaceuticals

HQ Location

Cambridge, MA, US

Employee Demographics

Tenure

Company Culture at Alnylam Pharmaceuticals

The employee experience below at Alnylam Pharmaceuticals, compared to a typical company.

Learn More

94% of employees at Alnylam Pharmaceuticals say it is a great place to work compared to 57% of employees at a typical U.S.-based company.

Alnylam Pharmaceuticals

94%

Typical Company

57%

Source: Great Place To Work® 2021 Global Employee Engagement Study.

97%

When I look at what we accomplish, I feel a sense of pride.

96%

People here are willing to give extra to get the job done.

96%

I'm proud to tell others I work here.

96%

I feel good about the ways we contribute to the community.

96%

When you join the company, you are made to feel welcome.

Why Work at Alnylam Pharmaceuticals?

See what employees say about what makes Alnylam Pharmaceuticals a great workplace. These words are drawn from employee comments on the Trust Index™ survey.